Coronavirus disease

Government of Canada COVID-19 Update for Indigenous Peoples and communities

Retrieved on: 
Friday, March 19, 2021
Medical specialties, Vaccination, Vaccine, Virology, Nunavik, Coronavirus disease, Health

There is a total of 48 confirmed positive cases in Nunavik, Quebec, with only 6 of those being active.

Key Points: 
  • There is a total of 48 confirmed positive cases in Nunavik, Quebec, with only 6 of those being active.
  • ISC is also continuing to support the vaccine roll out for Indigenous adults living in urban cities and towns across Canada.
  • ISC also continues to support communities by providing Personal Protective Equipment, as well as point of care testing equipment (COVID-19 tests).
  • That is why ISC, the CAF and partners will soon begin supporting vaccination programs in a number of remote/isolated on-reservecommunities, as well as a select number of larger on-reserve Indigenous communities.

$ 116.14 Billion Growth in Global Bakery Market 2020-2024 | Featuring Key Vendors Including Associated British Foods Plc, Britannia Industries Ltd., and Campbell Soup Co. | Technavio

Retrieved on: 
Friday, March 19, 2021
Articles, Health, Occupational safety and health, Public health, Infectious diseases, COVID-19 pandemic, Impact of the COVID-19 pandemic, COVID-19 lockdowns, Coronavirus disease

NEW YORK, March 19, 2021 /PRNewswire/ --The bakery market is expected to grow by USD116.14 billion during 2020-2024, according to Technavio.

Key Points: 
  • NEW YORK, March 19, 2021 /PRNewswire/ --The bakery market is expected to grow by USD116.14 billion during 2020-2024, according to Technavio.
  • The report offers a detailed analysis of the impact of the COVID-19 pandemic on the bakery market in optimistic, probable, and pessimistic forecast scenarios.
  • The bakery market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Get report snapshot here to get a detailed market share analysis of market participants during COVID-19 lockdown:

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Retrieved on: 
Thursday, March 18, 2021
Biotechnology, Pharmaceutical, General Health, Health, Medical devices, Infectious diseases, Hospitals, Clinical trials, Medical specialties, Health, Medicine, Intensive care medicine, COVID-19 drug development, Nucleotides, Remdesivir, Acute respiratory distress syndrome, Coronavirus disease, Mechanical ventilation, Treatment and management of COVID-19, Baricitinib, DEVENT (NCT04377620), the Ruxolitinib Expanded Access Program (EAP) in COVID-19, Jakafi® (ruxolitinib), Incyte

More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.

Key Points: 
  • More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.
  • The safety profile was generally consistent with hospitalized patients with COVID-19 and consistent with treatment with ruxolitinib.
  • We look forward to discussing the results of the DEVENT study with regulatory authorities in the United States.
  • The protocol will allow eligible patients with severe COVID-19 associated ARDS with disease severity requiring mechanical ventilation to receive ruxolitinib.

Oncologica is the First UK Genomic Testing Lab to Be Government Approved for Day 2 and Day 8 Testing

Retrieved on: 
Friday, March 19, 2021
Medical Supplies, Biotechnology, Other Health, White House, Federal Government, Health, Oncology, Research, Infectious diseases, Genetics, Public policy, Government, Science, Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Laboratory techniques, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction, COVID-19 testing, DNA sequencing, Coronavirus disease, Medical Supplies, Biotechnology, Other Health, White House, Federal Government, Health, Oncology, Research, Infectious diseases, Genetics, Public policy, Government, Science, Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, Laboratory techniques, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction, COVID-19 testing, DNA sequencing, Coronavirus disease

View the full release here: https://www.businesswire.com/news/home/20210318005848/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210318005848/en/
    The Oncologica Covid-19 PCR testing and genomic sequencing laboratories.
  • These testing capabilities will expedite the UKs return to work and mitigate the risk of superspreading Covid-19 variants in the population.
  • We are immensely proud of Oncologica achieving government approval as the first UK genomic testing laboratory in the UK to be put on the Governments provider list to undertake day 2 and day 8 Covid-19 PCR testing for travel which is no mean feat.
  • Read more at https://covid19.oncologica.com/coronafocus-day2-day8/
    Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK.

Study Examining 630,000 Patients Unveils COVID-19 Outcome Disparities Across Racial/Ethnic Lines

Retrieved on: 
Thursday, March 18, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Severe acute respiratory syndrome, Animal diseases, Coronavirus disease, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Variant of concern

The team looked at sociodemographic and clinical characteristics of patients who were part of the Providence healthcare system in Washington, Oregon and California.

Key Points: 
  • The team looked at sociodemographic and clinical characteristics of patients who were part of the Providence healthcare system in Washington, Oregon and California.
  • These patients had SARS-CoV-2 tests administered between March 1 and December 31 of 2020.
  • "All minority races/ethnicities faced increased odds of testing positive for SARS-CoV-2 and being hospitalized with COVID-19," said Chengzhen Dai, lead author of the study.
  • "Hispanic patients also exhibited increased morbidity, and Hispanic race/ethnicity was associated with increased odds of in-hospital mortality."

COVID-19 Startup Curative Reaches Its Milestone One Year Anniversary

Retrieved on: 
Thursday, March 18, 2021
Occupational safety and health, Health, Infectious diseases, Articles, COVID-19 testing, Coronavirus disease, COVID-19 pandemic

SAN DIMAS, Calif., March 18, 2021 /PRNewswire/ -- COVID-19 healthcare startup Curative marks its first anniversary this week of offering COVID-19 services with the goal of ending the current pandemic.

Key Points: 
  • SAN DIMAS, Calif., March 18, 2021 /PRNewswire/ -- COVID-19 healthcare startup Curative marks its first anniversary this week of offering COVID-19 services with the goal of ending the current pandemic.
  • Curative now employs over 5,000 team members, has expanded to 18 different states while completing nearly 18 million tests, to date.
  • "The one-year milestone of Curative is a big accomplishment not only for us as a company, but for our purpose and goal of helping end the COVID-19 pandemic," said Fred Turner, CEO and co-founder of Curative.
  • Curative was one of the first COVID-19 companies in the U.S. to offer scalable oral-fluid swab testingan alternative method to nasopharyngeal testing for COVID-19.

Global SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) Market Analysis and Forecast Model 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 18, 2021
Health, Biotechnology, Articles, Sarbecovirus, Branches of biology, Respiratory diseases, Bat virome, Severe acute respiratory syndrome, Coronavirus disease, Polymerase chain reaction, COVID-19 testing, DiaSorin

The "SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
  • SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • Annualized total SARS CoV-2 (COVID-19) PCR Tests market revenue by segment and market outlooks from 2015-2030.
  • Track device sales in the global and country-specific SARS CoV-2 (COVID-19) PCR Tests market from 2015-2030.

‘Frontiers in Medicine’ Publishes Organicell’s Case Report Demonstrating the Use of Zofin™ in the Treatment of COVID-19 Patients

Retrieved on: 
Thursday, March 18, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Occupational safety and health, Coronavirus disease, Public health, Zoonoses, Health

The report was published today in the journal Frontiers in Medicine.

Key Points: 
  • The report was published today in the journal Frontiers in Medicine.
  • We are proud to share that Frontiers in Medicine has published our case report on the exciting results of our Zofin treatment for respiratory failure induced by COVID-19 infection.
  • We look forward to continuing to research Zofin in COVID-19 patients through our clinical trials, said Albert Mitrani, CEO of Organicell.
  • This case report helps demonstrate the safety, accessibility, and feasibility of Zofin for respiratory failure induced by COVID-19 infection, said Dr. Mari Mitrani, Chief Science Officer of Organicell.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto announces European Approval for 25 Minute COVID-19 PCR Test

Retrieved on: 
Thursday, March 18, 2021
Molecular biology, Laboratory techniques, Natural sciences, Branches of biology, Life sciences, Biotechnology, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction, Coronavirus disease, COVID-19 testing, Draft:IGeneX

VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").

Key Points: 
  • VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").
  • Covid-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
  • With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic," said Hugh Rogers, CEO and Director of XPhyto.
  • For assay performance, Covid-ID Lab requires only a single 20-minute PCR thermal cycle without prior RNA extraction as part of the sample preparation.

Helping Reopen Texas: New Biodefense Technology Plays Pivotal Role in Providing Cleaner, Viral-Free Indoor Air Across the State

Retrieved on: 
Wednesday, March 17, 2021
Sarbecovirus, Articles, Respiratory diseases, Biological warfare, Natural sciences, Coronavirus disease, Occupational safety and health, Public health, Zoonoses, Heating, ventilation, and air conditioning, Biodefense, Filtration

"By following the CDC guidelines and providing clean, pathogen-free air in buildings, we are using science to engineer our way out of this public health crisis."

Key Points: 
  • "By following the CDC guidelines and providing clean, pathogen-free air in buildings, we are using science to engineer our way out of this public health crisis."
  • At the heart of this award-winning biodefense design is a proprietary heated mesh that works in conjunction with legacy air filtration found in HVAC systems.
  • The Biodefense Indoor Air Protection System is first line prevention technology against environmentally (airborne) mediated transmission of SARS-CoV-2 (COVID-19).
  • The heated biodefense filter can be retrofitted into commercial and home HVAC systems and/or deployed as a mobile unit equipped with powerful filtration capability.